See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. After it paid $430 million to settle a 2004 lawsuit over illegal ...

June 2 (Reuters) - Pfizer Inc has agreed to pay $325 million to resolve claims it defrauded insurers and other healthcare benefit providers by marketing Neurontin for unapproved uses, its second ...

Pfizer's potential liability on off-label Neurontin use just grew, thanks to a U.S. appeals court in Boston. The panel not only upheld a $142 million verdict in one lawsuit but also reinstated two ...

NEW YORK (Reuters) - Pfizer Inc has agreed to pay $190 million to settle a class action lawsuit alleging the pharmaceutical company took steps to delay market entry of generic versions of its epilepsy ...

Off-label marketing strikes again. Pfizer ($PFE) agreed to pay $325 million to wrap up claims that its Parke-Davis unit touted the epilepsy drug Neurontin for uses ...

NEW YORK, March 25 (Reuters) - Pfizer Inc violated federal racketeering law by improperly promoting the epilepsy drug Neurontin, a Boston jury found on Thursday, and the world's largest drugmaker was ...

Here's a depressing exchange in the litigation on Pfizer's anti-seizure med, Neurontin. It's between the doctor of Susan Bulger, who killed herself after taking the pill. Her family claims Pfizer knew ...

Drug companies spend billons of dollars each year trying to persuade doctors to prescribe their drugs. There are strict rules about what form that promotion can take. The rules are meant to ensure ...

(Reuters) - Pfizer Inc has agreed to pay $325 million to resolve claims it defrauded insurers and other healthcare benefit providers by marketing Neurontin for unapproved uses, its second settlement ...

Add Yahoo as a preferred source to see more of our stories on Google. The Pfizer logo is seen at their world headquarters in New York April 28, 2014.REUTERS/Andrew Kelly By Jonathan Stempel (Reuters) ...